DURECT (DRRX) - 2024 Q4 - Annual Results

Exhibit 99.1 DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif., March 26, 2025 /PRNewswire / -- DURECT Corporation (Nasdaq: DRRX) ...